First study of a new drug for advanced solid cancers
Part of Cancer clinical trials.
This Phase 1 trial tests a brand-new treatment (given at increasing doses) for people with advanced, unresectable, or metastatic solid tumors. It mainly looks at safety and how the drug behaves in the body, and it may help if standard treatments didn’t work or aren’t suitable.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be at least 18 years old.
- Have advanced solid cancer that cannot be removed by surgery or has spread, and standard treatment has not worked, cannot be tolerated, or is not appropriate.
- Have no more than one prior treatment “line” that included an immunotherapy like ICB (with limited protocol exceptions).
- Be able to have tumor biopsies before treatment and during treatment (unless an exception applies).
- Have measurable cancer (measurable disease) and be well enough to do daily activities (performance status 0–1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called BI 3822971 for people with advanced cancer that has not responded to standard treatments. The goal is to find the best dose that is safe and well-tolerated.
This early-phase trial tests a new oral drug (CSCJC3456) for people with advanced solid tumors, especially those with certain FGFR gene changes. It aims to see if the drug is safe and may help when other treatments have stopped working.
This study tests a new drug (BB-1709) for people with advanced solid tumors that haven't responded to standard treatments. The goal is to see if it's safe and how well it works.
This trial tests a new drug called DS-2243a for people with advanced solid tumors that have stopped responding to standard treatments. It targets a specific protein found in some cancers, and you need to have a particular immune system marker for it to work.
This trial tests a new drug that may help people with advanced solid tumors, including liver, stomach, and brain cancers. It is for patients whose cancer has not responded to standard treatments or who cannot have them. The study aims to find the right dose and check safety and effectiveness.
This Phase 1 trial tests a new drug called IUAb190708 designed to help your immune system fight advanced or recurrent solid cancers. The study will evaluate its safety, how your body handles it, and whether it works against your tumor.
Hear when a new Advanced Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.